Overview

Antiischemic Effects of Empagliflozin in Diabetic Patients With Refractory Angina

Status:
Completed

Trial end date:
2019-05-23

Target enrollment:
0

Participant gender:
All

Summary

this study was aimed to evaluation of antiangial effect of a new fda drug approval on angina in diabetic patient with refractory angina

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Isfahan University of Medical Sciences

Treatments:

Empagliflozin

Criteria

Inclusion Criteria:

1- T2DM patients over 18 years of age with CAD, who have had minimum 3-month refractory
Angina Pectoris (AP) in spite of using full medical treatment , and were not suitable
candidates for revascularization or CABG and reproducible angina, ischemic ST-segment
depression of at least 1 mm and limited exercise capacity on treadmill testing (3-9 minutes
on a modified Bruce protocol) while receiving full medical treatment .

Exclusion Criteria:

1- New York Heart Association functional class III to IV heart failure symptoms, 2- acute
coronary syndrome in the past 2 months, 3-any coronary revascularization during the study
period, 4- stroke or transient ischemic attack 5- hepatic or renal impairment, 6-prior
treatment with Empagliflozin 7- any relative or absolute contraindication to exercise test
or specific condition that preclude accurate interpretation of the
electrocardiogram(eg,Left bundle branch block(LBBB),resting ST depression more than 1 mm,
pre-excitation or digoxin use).

-